Metformin Reduces Risk of Diabetes by 22%, Results of Latest Meta-analysis

Written By :  Dr. Nandita Mohan
Published On 2024-07-17 12:30 GMT   |   Update On 2024-07-17 12:30 GMT
Advertisement

The addition of metformin to intensive Lifestyle Modifications (LSM) is an effective value addition among patients with pre-diabetes at high risk of progression to T2DM, a recent systematic review and meta-analysis study has concluded.

This study has been published in the June 2024 issue of Clinical Diabetology, Via Medica Journals.

The meta-analysis included 8,869 patients with prediabetes. Patients were grouped into two interventions- 4,328 in the metformin arm and 4,541 in the control arm (lifestyle modification/placebo).

Advertisement

Key highlights from the meta-analysis include:

  • The use of metformin resulted in a 22% relative risk reduction in the progression from prediabetes to diabetes compared to lifestyle modification and/or placebo.

This meta-analysis concludes that early intervention with metformin reduces the risk of type 2 diabetes in high-risk individuals with prediabetes1 . The huge global burden of prediabetes with an approximate 25% rate of conversion to diabetes represents the tip of the “sugary” iceberg.

These findings also co-relate with the most recently published analysis of UKPDS with regards to early intervention with metformin in T2D. Over the largest 42-year follow-up, the study showed that intensive glycemic control with metformin, compared to conventional glycemic control, led to a 20% reduction in the risk of death from any cause and a 31% reduction in the risk of myocardial infarction2.

*UKPDS: United Kingdom Prospective Diabetes Study

References:

1) Ghosal, S., Tippisetty, S., Polisetti, S., & Seshadri, K. G. (2024). Metformin for the Prevention of Prediabetes Progression to Type 2 Diabetes: A Systematic Review and Meta-Analysis. Clinical Diabetology, Via Medica Journals.

2) Adler, A. I., Coleman, R. L., Leal, J., Whiteley, W. N., Clarke, P. & Holman, R. R. (2024). Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). Lancet, doi:10.1016/S0140-6736(24)00537-3

Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News